GlassScriptPhysician profile
Mohammad F Ismail
NPI 1700811072
$2,507.27
in general payments reported to CMS, 2019-2025
34 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $622 · 2020: $278 · 2021: $359 · 2022: $564 · 2023: $562 · 2024: $123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $630 · Education: $54.58.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $629.92 |
| Education | $54.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $612.54 | 2019-2023 | |
| Novo Nordisk INC | $330.43 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $237.60 | 2021-2024 | Austedo Xr |
| Amgen INC. | $195.48 | 2019-2023 | Repatha, Otezla |
| Lilly USA, LLC | $107.87 | 2021-2023 | Emgality, Mounjaro, Jardiance |
| Novartis Pharmaceuticals Corporation | $100.35 | 2019-2022 | |
| Avanir Pharmaceuticals, INC. | $82.31 | 2019-2021 | |
| Pfizer INC. | $81.10 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $67.38 | 2022 | |
| Janssen Pharmaceuticals, INC | $58.14 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $57.49 | 2019 | |
| Mylan Specialty L.P. | $45.42 | 2022-2023 | Yupelri |
| Hikma Pharmaceuticals USA | $42.87 | 2019 | |
| Merck Sharp & Dohme LLC | $42.52 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.48 | 2022-2023 | Stiolto Respimat |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $36.28 | 2022-2023 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $34.67 | 2020 | |
| Dexcom, INC. | $32.81 | 2021-2023 | Dexcom G6 Transmitter |
| Celltrion USA INC. | $31.54 | 2024 | Zymfentra |
| Amarin Pharma, INC. | $29.04 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $23.84 | 2021 | |
| Allergan, INC. | $23.47 | 2019-2020 | |
| Glaxosmithkline, LLC. | $22.89 | 2023 | Shingrix, Arexvy |
| Shield Therapeutics INC | $20.94 | 2022 | |
| Intra-Sana Laboratories | $20.15 | 2023 | Glycate, Reltone 400 Mg, Reltone 200 Mg |
| Bayer Healthcare Pharmaceuticals INC. | $19.79 | 2022 | |
| Astellas Pharma US INC | $19.72 | 2022 | |
| Phadia US INC. | $18.16 | 2019 | |
| Currax Pharmaceuticals LLC | $14.73 | 2023 | Contrave |
| Ucb, INC. | $13.01 | 2023 | Cimzia |
| Acadia Pharmaceuticals INC | $11.97 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.95 | 2020 | |
| Ironwood Pharmaceuticals, INC | $11.80 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $11.53 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Ismail listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.